Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integra Lifesciences ( (IART) ) has provided an announcement.
On April 10, 2026, Integra LifeSciences’ subsidiaries amended their existing $150 million accounts receivable securitization facility, originally entered into on December 18, 2018, by executing updates to both the Receivables Financing Agreement and the Purchase and Sale Agreement with PNC Bank and other lenders. The amendments extend the facility’s scheduled termination date to April 10, 2029, and refine customary representations, covenants, and concentration limits on the securitized receivables, effectively preserving and enhancing the company’s liquidity framework and funding flexibility for its ongoing operations over the next several years.
The most recent analyst rating on (IART) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.
Spark’s Take on IART Stock
According to Spark, TipRanks’ AI Analyst, IART is a Neutral.
The score is held down primarily by the sharp 2025 profitability/revenue deterioration and weakened cash generation, with technicals also leaning weak (below key long-term moving averages). The earnings call provides partial offset via guidance for improved cash flow, modest growth, and deleveraging, but tariff/remediation and organic growth pressure keep risk elevated.
To see Spark’s full report on IART stock, click here.
More about Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company whose subsidiaries provide products and services to healthcare providers, and it uses financing structures such as accounts receivable securitization facilities to support liquidity and fund ongoing business needs. The company’s use of a bankruptcy-remote special purpose entity and securitized receivables underscores its reliance on structured finance to optimize its capital structure and manage working capital across its operating subsidiaries.
Average Trading Volume: 795,225
Technical Sentiment Signal: Strong Sell
Current Market Cap: $798.1M
See more insights into IART stock on TipRanks’ Stock Analysis page.